JP7714992B2 - 二重特異性抗体を有効成分として含む医薬組成物 - Google Patents

二重特異性抗体を有効成分として含む医薬組成物

Info

Publication number
JP7714992B2
JP7714992B2 JP2021162451A JP2021162451A JP7714992B2 JP 7714992 B2 JP7714992 B2 JP 7714992B2 JP 2021162451 A JP2021162451 A JP 2021162451A JP 2021162451 A JP2021162451 A JP 2021162451A JP 7714992 B2 JP7714992 B2 JP 7714992B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
arm
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021162451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022060182A (ja
JP2022060182A5 (enExample
Inventor
史朗 柴山
智也 手塚
マーク・スロスビー
コルネリス・アドリアン・デ・クルイフ
ピーテル・フォッコ・ヴァン・ロー
リンス・クロースター
ロベルタス・コルネリス・ローヴァーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of JP2022060182A publication Critical patent/JP2022060182A/ja
Publication of JP2022060182A5 publication Critical patent/JP2022060182A5/ja
Application granted granted Critical
Publication of JP7714992B2 publication Critical patent/JP7714992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021162451A 2020-10-02 2021-10-01 二重特異性抗体を有効成分として含む医薬組成物 Active JP7714992B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020167384 2020-10-02
JP2020167384 2020-10-02

Publications (3)

Publication Number Publication Date
JP2022060182A JP2022060182A (ja) 2022-04-14
JP2022060182A5 JP2022060182A5 (enExample) 2024-01-24
JP7714992B2 true JP7714992B2 (ja) 2025-07-30

Family

ID=81124684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021162451A Active JP7714992B2 (ja) 2020-10-02 2021-10-01 二重特異性抗体を有効成分として含む医薬組成物

Country Status (1)

Country Link
JP (1) JP7714992B2 (enExample)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
JP2011525808A (ja) 2008-06-27 2011-09-29 メルス・ベー・フェー 抗体産生非ヒト哺乳動物
CN106939050A (zh) 2017-03-27 2017-07-11 顺昊细胞生物技术（天津）股份有限公司 抗pd1和cd19双特异性抗体及其应用
WO2019009726A1 (en) 2017-07-06 2019-01-10 Merus N.V. BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
JP2019500405A (ja) 2015-10-23 2019-01-10 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
JP2011525808A (ja) 2008-06-27 2011-09-29 メルス・ベー・フェー 抗体産生非ヒト哺乳動物
JP2019500405A (ja) 2015-10-23 2019-01-10 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CN106939050A (zh) 2017-03-27 2017-07-11 顺昊细胞生物技术（天津）股份有限公司 抗pd1和cd19双特异性抗体及其应用
WO2019009726A1 (en) 2017-07-06 2019-01-10 Merus N.V. BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Oncology，2018年，Vol. 8, Article 285

Also Published As

Publication number Publication date
JP2022060182A (ja) 2022-04-14

Similar Documents

Publication Publication Date Title
US12091461B2 (en) Bispecific antibody
JP7688805B2 (ja) 二重特異性抗体
JP7574692B2 (ja) 二重特異性抗体
JP7714992B2 (ja) 二重特異性抗体を有効成分として含む医薬組成物
RU2814713C2 (ru) Биспецифическое антитело
RU2814713C9 (ru) Биспецифическое антитело
RU2796019C2 (ru) Биспецифическое антитело
RU2796019C9 (ru) Биспецифическое антитело
HK40062297A (en) Bispecific antibody
HK40036202B (zh) 双特异性抗体
HK40062297B (zh) 双特异性抗体
HK40036202A (en) Bispecific antibody
HK40069431A (en) Bispecific antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250630

R150 Certificate of patent or registration of utility model

Ref document number: 7714992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150